Cleared Traditional

SERUM 11-DESOXYCORTISOL I AS TRACER (K791740) - FDA 510(k) Clearance

Class I Chemistry device.

K791740 · Radioassay Systems Laboratories, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1979
Decision
17d
Days
Class 1
Risk

K791740 is an FDA 510(k) clearance for the SERUM 11-DESOXYCORTISOL I AS TRACER. Classified as Radioimmunoassay, Compound S (11-deoxycortisol) (product code JKB), Class I - General Controls.

Submitted by Radioassay Systems Laboratories, Inc. (Mchenry, US). The FDA issued a Cleared decision on September 27, 1979 after a review of 17 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1185 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Radioassay Systems Laboratories, Inc. devices

Submission Details

510(k) Number K791740 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 10, 1979
Decision Date September 27, 1979
Days to Decision 17 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
71d faster than avg
Panel avg: 88d · This submission: 17d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code JKB Radioimmunoassay, Compound S (11-deoxycortisol)
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1185
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.